The probiotics industry has attracted much attention in recent years. According to Euromonitor International, China has become the world's second largest consumer market for probiotics, and the market size is expected to reach 137.7 billion yuan in 2026. However, compared with foreign markets, the penetration rate of domestic probiotics is less than 10%, and the market potential is huge. This phenomenon has naturally attracted the attention of capital. IDG Capital, Richu Capital, Spade Capital, Frees Capital, Tiantu Capital and other well-known investment institutions have entered the probiotics industry, and major institutions are also grabbing chips in the probiotics industry chain. Behind the favor of capital in the probiotics industry is the importance of the core technology of probiotics. The independent research and development of probiotic core raw material strains plays an important role in the national microbial science and technology level. China's probiotics industry started late, and 85% of the probiotic raw material market is currently monopolized by American companies. Therefore, the research and development of localized strains is imperative. Large European and American companies continue to carry out mergers and acquisitions in the probiotics industry, which also makes local probiotic companies face market challenges. Probiotics, this microorganism plays an important role in our health, it can maintain the balance of intestinal microbiome, help our intestines fight off germs, and enhance immunity.
However, the domestic probiotics industry is facing a series of challenges, such as difficulties in independent research and development, high technical barriers, and other problems. According to the data of bluewe**e organization, the global probiotics market continues to expand and the market has broad prospects. Although facing many difficulties, more and more domestic enterprises have joined the probiotics industry and have made certain breakthroughs. Recently, By-Health, a domestic dietary supplement company, has established a microecological R&D center laboratory, which is committed to the research and development of probiotics and the health of the human microecosystem. Probiotics are microorganisms that are beneficial for our gut health. It can help maintain the balance of intestinal microecology, inhibit the growth of harmful bacteria, and enhance intestinal resistance. It is difficult for the probiotics industry to independently develop core raw material strains, and the technical barriers are high. Due to the relatively late start of China's probiotic industry, probiotic strains with independent intellectual property rights are scarce, and the core technology of the industry is heavily dependent on leading foreign companies. According to the data of bluewe**e organization, the global probiotics market continues to expand and the market has broad prospects. The global probiotics market is expected to grow at a growth rate of 8The compound annual growth rate of 7% reached 934$900 million.
The importance of the probiotics industry and the technical difficulties have also pushed up the future growth space of the probiotics market. Although it is difficult to independently develop probiotic strains, more and more domestic companies have joined the probiotics industry and have made certain breakthroughs. Recently, By-Health, a leading domestic dietary supplement company, has established a microecological R&D center laboratory, which is committed to the research and development of probiotics and the health of the human microecosystem. By-Health is a leading enterprise in the field of dietary supplements in China, and they have recently built a microecological R&D center laboratory and put it into use. The laboratory consists of a probiotic R&D platform and a synthetic biotechnology platform, relying on modern microbiology and biomanufacturing technology, and is committed to the research of human microecosystem health. This marks the active exploration and efforts of domestic enterprises in the probiotics industry, and has made a new breakthrough in the independent research and development of probiotic strains and the improvement of technological innovation capabilities. This is of positive significance for the development of China's probiotics industry and human health. In the context of the rapid growth of the global probiotics market, domestic enterprises have gradually emerged in the probiotics industry, showing strong development potential.
By-Health's move not only promotes the progress of probiotic industry technology, but also brings more healthy choices to consumers. The future of the probiotics industry is full of hope, and I believe that with the continuous breakthrough and innovation of technology, we will usher in more surprises about probiotics. The establishment of Tomson Bio-Health probiotics R&D platform means that the company can rely on its own laboratory to carry out research on key technologies such as probiotic resource mining, microbial physiological characteristics and high-density fermentation, and has formed independent R&D and transformation capabilities. This is not only a starting point, but a higher starting point. As early as 2016, By-Health began to work on the research and transformation and application of probiotic strains, and has achieved rich results in scientific research and industrial transformation and application. It is understood that at present, Tomson Beijian has obtained 2 new strains of its own patents and more than 30 kinds of customized raw materials. Among them, the local high-quality strain LPB27 has obtained a number of Chinese and international patents, and the research results have been published in well-known scientific journals. This year, the clinical research articles of By-Health in the field of probiotic evidence-based research have been published in the internationally renowned journal "gut microbes" in the field of intestinal health.
In addition, Lactobacillus paracasei LPB27 has been applied to the Australian probiotic brand Lifespace. With the rapid growth of Lifespace's domestic products, By-Health has further opened up the upstream and downstream of the industrial chain on the basis of years of deep cultivation of channels. In addition to the field of probiotics, By-Health has also set its sights on another hot field - synthetic biology. Hailed as the third biotechnology revolution, synthetic biotechnology is a key technology that crosses multiple disciplines and is believed to change the future of mankind. In view of this, Tomson By-Health is actively deploying in this field. The continuous innovation and diversified development of By-Health have brought a broader development space for the company and provided consumers with more and better health products. Synthetic biology is becoming the focus of attention of **, scientific research institutions and biomanufacturing companies around the world. The development of this emerging field not only proposes solutions to issues such as climate change, resources, energy, environment, food and healthcare, but also provides new possibilities for the sustainable development of mankind.
Focusing on synthetic biology, By-Health is committed to building four major technology platforms, including a large-scale preparation platform for microbial cell factories, a high-throughput screening platform, a precision fermentation platform, and an efficient separation, purification and preparation platform, focusing on the synthetic biology development and industrialization transformation research of functional food raw materials, high value-added chemicals, high-value natural products and engineered probiotics. At the same time, the company is also making an important layout in the joint probiotics research and development platform to ensure the company's future reserve of high-quality raw materials, which is also one of its core strategic goals of independent research and development of raw materials. In order to gain a foothold in the field of synthetic biology, enterprises need to have strong scientific research and technical strength. By-Health has invested a lot of resources to set up the Institute of Nutrition and Health, and invited well-known experts at home and abroad to serve as members of the academic expert committee, and has formed a professional team of more than 200 people, including doctors and masters, covering medicine, nutrition, microbiology and other fields. These measures fully demonstrate the company's comprehensive strength in R&D capabilities, operational capabilities and financial capabilities.
In 2022, By-Health formulated the 2030 core goals and action outlines for the transformation of strong technology enterprises, and clarified the specific goals of the transformation: national invention patents for raw materials and formulas, research and development of new and heavy-function large-scale products, and forward-looking basic research such as anti-aging and precision nutrition. Focusing on these goals, the company's corresponding strategic achievements are also gradually implemented. For example, the company has made an important breakthrough in formula patents, not only successfully developing the high-quality strain Lactobacillus paracasei LPB27, but also independently developing a new collagen peptide with an average molecular weight of less than 1500 Da and rich in glycosaminoglycans, an important component of the dermis. These results have been successfully applied to YEP's oral skin nutrition products, injecting new impetus into the company's development. To sum up, the development of the field of synthetic biology has brought a broader development space for enterprises, and through the support of strong scientific research strength and long-term strategy, By-Health is gradually realizing its own development goals and injecting new vitality into the development of the industry. The latest research results recently released by By-Health are exciting. They have collaborated with a number of authoritative institutions to publish experimental results on improving blood flow health in the Chinese population, as well as studies on NAD+ and aging.
The findings were hailed as a "new milestone in anti-aging" by the world-renowned scientific journal NatureMetabolism. These achievements are not only a great contribution to the scientific community, but also a valuable asset to human health. Guided by the scientific nutrition strategy, By-Health is committed to improving human health and improving the quality of life. These milestones will undoubtedly draw a brighter future for the future of health.